Coats' disease: treatment with intravitreal bevacizumab and laser photocoagulation.
Stergiou
Panagiotis K
PK
Symeonidis
Chrysanthos
C
Dimitrakos
Stavros A
SA
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005122:Exudates and Transudates / Q000378:metabolism*; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000150:complications / Q000628:therapy*; D008297:Male; D012163:Retinal Detachment / Q000209:etiology / Q000628:therapy*; D012164:Retinal Diseases / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D013684:Telangiectasis / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab